BACKGROUND: This study was aimed to investigate the correlation between CYP2C19 and ABCB1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel. METHODS: A total of 168 patients with coronary heart disease who underwent PCI operation and received clopidogrel treatment were enrolled. Dual antiplatelet therapy was applied to the treatment of patients for 2 years. Thromboelastography was used to test the efficiency of blood coagulation. Polymerase chain reaction (PCR) was used to detect CYP2C19 and ABCB1 3435CT polymorphisms. One-year follow-up visit was carried out to record the incidence of cardiovascular adverse events after drug-eluting stent implantation was inset. RESULTS: Follow-up visit results suggested that the patients with high on-treatment platelet reactivity (HPR) had a higher recurrence rate of cardiovascular adverse events after PCI operation and clopidogrel treatment. Gene polymorphism testing results indicated that patients with CYP2C19*3 had a significantly higher incidence of HPR, whereas CYP2C19*2 and ABCB1 3435CT were not significantly correlated with HPR. Multivariable logistic regression analysis showed that CYP2C19*3 might be an independent predictive factor of post-PCI HPR. In addition, CYP2C19*3 as well as post-PCI HPR could function as independent predictive factors of cardiovascular adverse events. CONCLUSION: CYP2C19*3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment.
BACKGROUND: This study was aimed to investigate the correlation between CYP2C19 and ABCB1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in patients with coronary artery disease treated with clopidogrel. METHODS: A total of 168 patients with coronary heart disease who underwent PCI operation and received clopidogrel treatment were enrolled. Dual antiplatelet therapy was applied to the treatment of patients for 2 years. Thromboelastography was used to test the efficiency of blood coagulation. Polymerase chain reaction (PCR) was used to detect CYP2C19 and ABCB1 3435CT polymorphisms. One-year follow-up visit was carried out to record the incidence of cardiovascular adverse events after drug-eluting stent implantation was inset. RESULTS: Follow-up visit results suggested that the patients with high on-treatment platelet reactivity (HPR) had a higher recurrence rate of cardiovascular adverse events after PCI operation and clopidogrel treatment. Gene polymorphism testing results indicated that patients with CYP2C19*3 had a significantly higher incidence of HPR, whereas CYP2C19*2 and ABCB1 3435CT were not significantly correlated with HPR. Multivariable logistic regression analysis showed that CYP2C19*3 might be an independent predictive factor of post-PCI HPR. In addition, CYP2C19*3 as well as post-PCI HPR could function as independent predictive factors of cardiovascular adverse events. CONCLUSION:CYP2C19*3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment.
Authors: Christopher P Nelson; Anuj Goel; Adam S Butterworth; Stavroula Kanoni; Tom R Webb; Eirini Marouli; Lingyao Zeng; Ioanna Ntalla; Florence Y Lai; Jemma C Hopewell; Olga Giannakopoulou; Tao Jiang; Stephen E Hamby; Emanuele Di Angelantonio; Themistocles L Assimes; Erwin P Bottinger; John C Chambers; Robert Clarke; Colin N A Palmer; Richard M Cubbon; Patrick Ellinor; Raili Ermel; Evangelos Evangelou; Paul W Franks; Christopher Grace; Dongfeng Gu; Aroon D Hingorani; Joanna M M Howson; Erik Ingelsson; Adnan Kastrati; Thorsten Kessler; Theodosios Kyriakou; Terho Lehtimäki; Xiangfeng Lu; Yingchang Lu; Winfried März; Ruth McPherson; Andres Metspalu; Mar Pujades-Rodriguez; Arno Ruusalepp; Eric E Schadt; Amand F Schmidt; Michael J Sweeting; Pierre A Zalloua; Kamal AlGhalayini; Bernard D Keavney; Jaspal S Kooner; Ruth J F Loos; Riyaz S Patel; Martin K Rutter; Maciej Tomaszewski; Ioanna Tzoulaki; Eleftheria Zeggini; Jeanette Erdmann; George Dedoussis; Johan L M Björkegren; Heribert Schunkert; Martin Farrall; John Danesh; Nilesh J Samani; Hugh Watkins; Panos Deloukas Journal: Nat Genet Date: 2017-07-17 Impact factor: 38.330
Authors: G M Podda; E Grossi; T Palmerini; M Buscema; E A Femia; D Della Riva; S de Servi; P Calabrò; F Piscione; D Maffeo; A Toso; C Palmieri; M De Carlo; D Capodanno; P Genereux; M Cattaneo Journal: Int J Cardiol Date: 2017-03-18 Impact factor: 4.164
Authors: Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Joseph R Walker; Tabassome Simon; Elliott M Antman; Eugene Braunwald; Marc S Sabatine Journal: Lancet Date: 2010-10-16 Impact factor: 79.321
Authors: Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245